Home » Stocks » Relay Therapeutics

Relay Therapeutics, Inc. (RLAY)

Stock Price: $37.84 USD 1.25 (3.42%)
Updated Aug 5, 2020 4:00 PM EDT - Market closed
After-hours: $38.00 +0.16 (0.42%) Aug 5, 4:43 PM

Stock Price Chart

Key Info

Market Cap 3.29B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 86.88M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $37.84
Previous Close $36.59
Change ($) 1.25
Change (%) 3.42%
Day's Open 36.25
Day's Range 35.70 - 39.73
Day's Volume 258,529
52-Week Range 33.19 - 49.89

More Stats

Market Cap 3.29B
Enterprise Value 2.98B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 86.88M
Float 2.14M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 8.91
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 310.53M
Net Cash / Share 3.57
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-84.05-49.89
Net Income-75.31-48.79
Shares Outstanding3.452.49
Earnings Per Share-21.82-19.63
Operating Cash Flow-66.13-44.14
Capital Expenditures-7.98-1.68
Free Cash Flow-74.12-45.82
Cash & Equivalents357422
Total Debt24.830.18
Net Cash / Debt332422
Book Value-180-111
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Relay Therapeutics, Inc.
Country United States
Employees 122
CEO Sanjiv K. Patel

Stock Information

Ticker Symbol RLAY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RLAY
IPO Date July 16, 2020


Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.